Genscript Biotech Corporation (HKG:1548)
Hong Kong
· Delayed Price · Currency is HKD 13.62
+0.09 (0.67%)
Apr 29, 2026, 4:08 PM HKT
Genscript Biotech Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -532.83 | 2,962 | -95.48 | -226.85 | -358.71 | Upgrade
|
| Depreciation & Amortization | 73.3 | 75.71 | 71.88 | 61.18 | 45.86 | Upgrade
|
| Other Amortization | 0.74 | 1.96 | 2.17 | 3.07 | 1.92 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.87 | 1.19 | 0.69 | 0.77 | 0.91 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 45.51 | 11.66 | 11.48 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 391.56 | -0.19 | -2.43 | 3.64 | -0.53 | Upgrade
|
| Loss (Gain) on Equity Investments | 320.38 | 39.07 | 1.38 | 0.03 | - | Upgrade
|
| Stock-Based Compensation | 14.79 | 76.52 | 60.59 | 65.15 | 39.69 | Upgrade
|
| Provision & Write-off of Bad Debts | -1.33 | 6.56 | 4.78 | 1.15 | 0.93 | Upgrade
|
| Other Operating Activities | 59.87 | -3,020 | 264.61 | -204.38 | -9.51 | Upgrade
|
| Change in Accounts Receivable | -16.49 | 95.46 | -116.99 | 38.07 | 1.57 | Upgrade
|
| Change in Inventory | -8.58 | -10.53 | -3.93 | -19.53 | -15.14 | Upgrade
|
| Change in Accounts Payable | 6.95 | 15.99 | -37.03 | 25.58 | 8.07 | Upgrade
|
| Change in Unearned Revenue | 1.98 | -35.75 | 100.77 | 6.76 | 3.54 | Upgrade
|
| Change in Other Net Operating Assets | 14.31 | 20.28 | -29.74 | 113.59 | 144.6 | Upgrade
|
| Operating Cash Flow | 325.52 | 75.65 | -286.91 | -120.29 | -136.79 | Upgrade
|
| Operating Cash Flow Growth | 330.32% | - | - | - | - | Upgrade
|
| Capital Expenditures | -82.13 | -195.79 | -252.45 | -216.11 | -133.04 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.37 | 0.24 | 0.24 | 0.09 | 0.27 | Upgrade
|
| Sale (Purchase) of Intangibles | -1.76 | -1.24 | -4.05 | -2.27 | -4.35 | Upgrade
|
| Investment in Securities | -83.14 | -806 | -101.72 | -219.75 | -82.44 | Upgrade
|
| Other Investing Activities | -5.29 | -453.57 | 0.25 | -5.25 | 7.02 | Upgrade
|
| Investing Cash Flow | -171.95 | -1,456 | -357.73 | -443.3 | -212.55 | Upgrade
|
| Long-Term Debt Issued | 219.09 | 102.61 | 74.39 | 33.06 | 26.04 | Upgrade
|
| Long-Term Debt Repaid | -142.34 | -67.74 | -34.06 | -7.39 | -74.94 | Upgrade
|
| Total Debt Repaid | -142.34 | -67.74 | -34.06 | -7.39 | -74.94 | Upgrade
|
| Net Debt Issued (Repaid) | 76.74 | 34.86 | 40.33 | 25.67 | -48.89 | Upgrade
|
| Issuance of Common Stock | 6.02 | 13.49 | 17.65 | 228.13 | 951.23 | Upgrade
|
| Other Financing Activities | -2.51 | 18.17 | 1,010 | 165.52 | -0.19 | Upgrade
|
| Financing Cash Flow | -144.89 | 66.52 | 1,068 | 419.32 | 902.14 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.82 | -0.22 | -1.22 | -12.7 | -0.89 | Upgrade
|
| Net Cash Flow | 10.5 | -1,314 | 422.4 | -156.97 | 551.91 | Upgrade
|
| Free Cash Flow | 243.39 | -120.14 | -539.36 | -336.41 | -269.83 | Upgrade
|
| Free Cash Flow Margin | 25.36% | -20.21% | -96.23% | -53.76% | -55.06% | Upgrade
|
| Free Cash Flow Per Share | 0.11 | -0.06 | -0.26 | -0.16 | -0.13 | Upgrade
|
| Cash Interest Paid | 11.54 | 4.68 | 3.19 | 2.04 | 1.58 | Upgrade
|
| Cash Income Tax Paid | 29.24 | 16.6 | 2.66 | -0.66 | 0.71 | Upgrade
|
| Levered Free Cash Flow | -67.82 | 425.25 | -305.28 | -342.98 | -176.43 | Upgrade
|
| Unlevered Free Cash Flow | -57.01 | 430.27 | -301.7 | -334.69 | -174.95 | Upgrade
|
| Change in Working Capital | -1.82 | 85.44 | -86.91 | 164.47 | 142.65 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.